VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Sept. 28, 2005) - EnWave Corporation (TSX VENTURE:ENW) is pleased to announce that it has manufactured and sold to the University of British Columbia a 1 kW laboratory model vacuum microwave dehydration (VMD) unit, specifically designed for application of EnWave's proprietary radiant energy - vacuum (REV) technology to pharmaceutical and biomedical materials. The planned design and manufacture of this unit and the research project which it supports were announced in our news release of February 8, 2005.
"There is a great deal of interest in this technology from scientists in different fields of health research, including a team in orthopedics, dental surgeons and periodontists, and biomaterials scientists," said Dr. Helen Burt, Angiotech Professor of Drug Delivery in the Faculty of Pharmaceutical Sciences at the University of British Columbia. "My research personnel are in the process of developing the techniques for loading drugs such as antibiotics and growth factors into the sponges and determining the most appropriate biomaterials for these applications."
EnWave is also pleased to announce that it has received a new order for the purchase of a prototype 2 kW VMD unit from the Department of Agricultural and Bio-resource Engineering at the University of Saskatchewan. The receipt of this purchase order will bring the number of VMD units sold by EnWave to five.
"We feel confident that the continued interest and purchase of research VMD units by major universities and technical institutions will provide a solid foundation for the commercial development of our technology," said EnWave's President Dr. Tim Durance.
EnWave is a research and development company developing commercial applications of vacuum microwave ("VM") technology using specially designed VM processing equipment. EnWave's mission is to lead the development of VM processing systems for industrial applications in the food, feed, pharmaceutical, nutraceutical and chemical industries. Applications of the technology enable manufacturers to produce innovative, high quality products that cannot be produced using current techniques. Many of the processes producing these products have been granted patents, recognizing their innovative nature.
There are forward-looking statements contained herein, including without limitation statements containing the words "great deal of interest", "provide a solid foundation for the commercial development of our technology" and "innovative". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, EnWave's stage of development, lack of product revenues, additional capital requirements, risks associated with research and development and obtaining regulatory approval to market EnWave's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
This press release was prepared on behalf of the Board of Directors, which accepts full responsibility for its content.
ON BEHALF OF THE BOARD
Dr. Tim Durance, President, C.E.O. and Corporate Secretary
FOR FURTHER INFORMATION PLEASE CONTACT:
Dr. Tim Durance
(604) 806-6112 (FAX)